Company Description

Diamyd Medical is a drug development company in the field of diabetes. It is developing two disease-modifying treatments: the antigen-specific immunotherapy Diamyd®, and the oral regenerative and immunomodulatory therapy Remygen®. Diamyd® and Remygen® are being evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, the dysfunction and loss of the insulin-producing cells of the pancreas.

Sector: Health Care
Market: First North Stockholm
Ticker: DMYD B

Webpage
Penser Play

 

 

Latest research | 24 Apr 2024 | Diamyd Medical

An exciting future on the cards

Read research
Latest research | 26 Jan 2024 | Diamyd Medical

All eyes on DIAGNODE-3

Read research
Latest research | 9 Nov 2023 | Diamyd Medical

Cash chest refilled

Read research
Latest research | 12 Oct 2023 | Diamyd Medical

Rights issue to be implemented

Read research
Latest research | 30 Jun 2023 | Diamyd Medical

Money in the bank

Read research
Latest research | 20 Apr 2023 | Diamyd Medical

Diabetes deal

Read research
Latest research | 11 Apr 2023 | Diamyd Medical

In a solid position

Read research